Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Analysis of transcriptional changes associated with acquired resistance to docetaxel in HR+/HER2- breast cancer cell line MCF-7

ABSTRACT: Resistance to neoadjuvant chemotherapy in HR+/HER2- breast cancers is increasingly recognized as a consequence of tumor cell plasticity rather than fixed genetic alterations. Large-scale genomic analyses comparing tumors before and after chemotherapy have failed to identify recurrent mutations that consistently account for treatment failure. Instead, resistance is thought to arise predominantly through non-genetic, adaptive mechanisms, including the acquisition of gene expression changes that allow cancer cells to survive chemotherapy-induced stress and later re-enter proliferative programs.To uncover transcriptional adaptations to docetaxel, a chemotherapeutic agent used in the NAC clinical setting, we performed bulk RNA-sequencing on parental and docetaxel-resistant MCF-7 cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE327278 | GEO | 2026/07/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from docetaxel-resistant prostate cancer cell lines

2012-01-01 | GSE33455 | GEO

Patient-derived cell lines unveil COL1A2 as a predictor of docetaxel resistance in breast cancer

Project description:Breast cancer is the most common type of malignant tumour among women globally, with a major cause of cancer-related mortality worldwide. Chemoresistance presents a significant challenge in breast cancer therapy and serves as the primary factor contributing to tumour recurrence and metastasis. At present, there is a paucity of effective predictive strategies in this field. In this study, we successfully established patient-derived primary cancer cell lines (PCCL) from four patients with HR+/HER2- breast cancer (Luminal B, HER2 non-amplified) using primary cell culture technology. The retention of the original tumour's pathological characteristics and drug response heterogeneity was confirmed. The aim was to delve into the mechanisms and predictive models underlying chemotherapy resistance in HR+/HER2- breast cancer. Our investigation revealed varying sensitivities of PCCL to taxanes, including docetaxel. Through RNA sequencing and protein-protein interaction (PPI) network analysis, we discovered that the COL1A2 gene is significantly overexpressed in HR+/HER2- breast cancer patients exhibiting docetaxel resistance. Notably, this overexpression shows a negative correlation with the patients' pathological complete response rate (pCR) and recurrence-free survival (RFS). In functional assays, higher COL1A2 expression correlated with diminished docetaxel sensitivity in HR+/HER2-negative breast cancer cells. These findings are consistent with the imaging assessments and postoperative pathological outcomes of patients who underwent neoadjuvant therapy (AC-T regimen). These findings suggest that COL1A2 is associated with reduced chemotherapy sensitivity in HR+/HER2- breast cancer and may serve as a candidate biomarker to guide neoadjuvant taxane selection. Overall, this study provides a novel theoretical foundation for selecting neoadjuvant chemotherapy drugs for advanced breast cancer patients.

2026-02-18 | GSE319840 | GEO

RNA-seq analysis of TCEAL1 knock down with/without docetaxel treatment to enhance docetaxel efficacy in prostate cancer

Project description:Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit due to emerging resistance. This experiment studies effect of TCEAL1 gene knock down with/without docetaxel treatment. The TCEAL1 gene was identified as the top candidate gene in vivo CRISPR/Cas9 screen.

2020-10-07 | E-MTAB-9484 | biostudies-arrayexpress

Expression data from docetaxel-resistant prostate cancer cell lines

Project description:Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer. However, most patients eventually develop resistance to this treatment. The aim of the study was to identify key molecular genes and networks associated with docetaxel resistance in 2 models of docetaxel-resistant castration-resistant prostate cancer cell lines. DU-145 and PC-3 cells were converted to docetaxel-resistant cells, DU-145R and PC-3R, respectively. Whole-genome arrays were used to compare global gene expression between these 4 cell lines. Arrays were performed by triplicate for each cell line.

2012-01-01 | E-GEOD-33455 | biostudies-arrayexpress

A Phase II Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Docetaxel and Carboplatin with Trastuzumab and/or Lapatinib in Patients with HER2+ Breast Cancer [Baseline]

Project description:Adjuvant docetaxel, carboplatin, and trastuzumab (TCH) is a standard regimen for HER2+ breast cancer. Dual HER2-blockade with lapatinib (L) and trastuzumab demonstrated significant activity in the metastatic and neoadjuvant settings. This study evaluates neoadjuvant TC plus trastuzumab (H) and/or lapatinib (L). This study demonstrated a similar pCR rate with TCH and TCHL and a lower rate of pCR with TCL. Treatment-related toxicity limited the ability for participants to receive protocol-specified chemotherapy and HER2-targeted therapy in the TCHL Arm.

2019-05-08 | GSE130786 | GEO

2019-05-08 | GSE130787 | GEO

Association of immune related expression profile with sensitivity to neoadjuvant chemotherapy using docetaxel, cisplatin and 5-fluorouracil in esophageal squamous cell carcinoma.

Project description:Neoadjuvant chemotherapy (NAC) followed by surgery is one of the standard therapeutic approaches for patients with locally advanced esophageal carcinoma in Japan. Recently, JCOG1109 study revealed that NAC with docetaxel, cisplatin and 5-fluorouracil (5-FU) (DCF-NAC) is superior to NAC with cisplatin and 5-FU, and has become the standard preoperative chemotherapy. By using microarray, we have previously investigated expression profiles of endoscopic biopsies of patients with esophageal squamous cell carcinoma (ESCC) before DCF-NAC (preNAC) and identified 17 molecules as predictive biomarkers for pathologically complete response to DCF-NAC. Here, we re-grouped our previous dataset based on the histopathological response grade with an addition of several microarray profiles (altogether 5 non-tumors, 12 highly resistant cancers and 27 sensitive cancers) and re-analyzed by bioinformatic web tools, including DAVID, GSEA, UALCAN and CIBERSORTx. We identified 204 genes as differentially expressed genes (DEGs) between highly resistant and sensitive groups. A number of DEGs were related to immune response and expressed higher in sensitive group. By UALCAN, 28 of the top 50 DEGs showed that their high expression were associated with favorable prognosis (p<0.25). Among them, 18 DEGs reached significance (p<0.05), suggesting that patients with high expression of these genes might have benefited from chemotherapy and thus had better outcome. We further showed distribution of the cells expressing CXCL9 mRNA, one of the prognosis related DEGs, in preNAC biopsy tissues of DCF-sensitive case. In conclusion, our data may provide useful information to establish predictive and effective methods for DCF-NAC in ESCC.

2023-11-15 | GSE225178 | GEO

Expression data from docetaxel-resistant and cabazitaxel-resistant prostate cancer cell lines

Project description:Docetaxel and cabazitaxel are the chemotherapy agents used in castration-resistant prostate cancer. However, most patients eventually develop resistance to these treatments. The aim of the study was to identify key molecular genes and networks associated with taxanes resistance in 2 models of docetaxel-resistant and cabazitaxel-resistant castration-resistant prostate cancer cell lines.

2020-10-25 | GSE158494 | GEO

Gene expression data of sensitive, Docetaxel resistant and Paclitaxel resistant MDA-MB-231 Cells

Project description:The taxanes, namely Paclitaxel and Docetaxel, are important and widely used cancer chemotherapy drugs in the treatment of invasive and metastatic human breast cancer. Although treatment with the taxanes is beneficial to many patients, drug-responsive tumors in patients with metastatic breast cancer often display resistance to these drugs, either initially or over time following the continued administration of chemotherapy drugs. To investigate the patterns of cross-resistance with the taxane drugs and to identify potential mechanisms of resistance, we generated a series of MDA-MB-231 taxane resistant cell lines. We then used microarrays to determine gene expression differences between sensitive, Docetaxel and Paclitaxel resistant MDA-MB-231 cells. RNA isolated from three independent passages of sensitive, Docetaxel and Paclitaxel resistant cell lines and purified using the Qiagen RNeasy Mini Kit. Total RNA was processed and hybridized to Affymetrix Genechip HU133A arrays.

2011-04-22 | E-GEOD-28784 | biostudies-arrayexpress

Pre-existing cell subpopulations in primary prostate cancer tumors display surface fingerprints of docetaxel-resistant cells

Project description:Docetaxel resistance presents a significant obstacle in the treatment of prostate cancer (PCa), resulting in unfavorable patient prognoses. Intratumoral heterogeneity, often associated with epithelial-to-mesenchymal transition (EMT), has previously emerged as a phenomenon facilitating adaptations to various stimuli, thus promoting cancer cell diversity and eventually resistance to chemotherapy, including docetaxel. Hence, comprehending intratumoral heterogeneity is essential for better patient prognosis and the development of personalized treatment strategies. To address this, we employed a high-throughput single-cell flow cytometry approach to identify a specific surface fingerprint associated with docetaxel-resistance in PCa cells and complement it with protein composition analysis of extracellular vesicles We further performed validation of selected antigens using docetaxel-resistant patient-derived xenografts in vivo and determine a 6-molecule surface fingerprint associated with docetaxel resistance in primary PCa specimens. Remarkably, we observed consistent overexpression of CD95 and SSEA-4 surface antigens in both in vitro and in vivo docetaxel-resistant models and in a cell subpopulation of primary PCa tumors exhibiting EMT features. Furthermore, CD95, along with the essential enzymes involved in SSEA-4 synthesis, ST3GAL1, and ST3GAL2, displayed a significant increase in PCa patients undergoing docetaxel-based therapy, correlating with poor survival outcomes. In conclusion, we demonstrate that the identified 6-molecule surface fingerprint associated with docetaxel resistance pre-exists in a subpopulation of primary PCa tumors before docetaxel treatment. This fingerprint, therefore, deserves further validation as a promising tool for predicting docetaxel response in PCa patients before therapy initiation.

2025-05-06 | PXD050073 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data